http://www.lsis.com/goto/r6/rss 2010-06-23T11:10:04+01:00 text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97f%FB%1Cu%7C%7E WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the promotion to vice president of two executive directors Godfrey Amphlett, Ph.D., and Robert J. Lutz, Ph.D. who have played central roles in establishing ImmunoGen s highly successful product development capabilities. These functions complement the Company s strong research capabilities in ImmunoGen s advancement of its own novel anticancer compounds and the industry-leading target-to-commercial product expertise the Company provides to its partners. ImmunoGen has transitioned from being an organization with strong research to one (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97f%FB%1Cy%7C%7C SUMMARY: Recently, several methods for analyzing phenotype data have been published, but only few are able to cope with data sets generated in different studies, with different methods, or for different species. We developed an online-system in which more than 300,000 phenotypes from a wide variety of sources and screening methods can be analyzed together. Clusters of similar phenotypes are visualized as networks of highly similar phenotypes, inducing gene groups useful for functional analysis. This system is part of PhenomicDB, providing the world's largest cross-species phenotype data collection with a tool to mine its wealth of information. AVAILABILITY: Freely available at (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97f%FB%17%7Ez%7E Hepatobiliary elimination via canalicular efflux transport proteins plays a key role in the clearance of endo- and xenobiotics. Correct membrane localization and coordinated action of the transport systems are essential for vectorial transport of drugs from blood into the bile. Whilst basolaterally localized uptake transporters are responsible for the inward transport of substances from the blood into the hepatocyte, apically expressed ATP-dependent transport proteins such as Pglycoprotein (P-gp), multidrug resistance-associated protein (Mrp2) and breast cancer resistance protein (Bcrp) mediate the outward efflux into the bile canaliculus. Using sandwich-cultured rat hepatocytes we have (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97f%FB%15tz%7D Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesteryl esters from the atheroprotective high density lipoprotein (HDL) to the proatherogenic low density lipoprotein cholesterol (LDL) and very low density lipoprotein cholesterol (VLDL) leading to lower levels of HDL but raising the levels of proatherogenic LDL and VLDL. Inhibition of CETP is considered a potential approach to treat dyslipidemia. However, discussions regarding the role of CETP-mediated lipid transfer in the development of atherosclerosis and CETP inhibition as a potential strategy for prevention of atherosclerosis have been controversial. Although many animal studies (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v6/%3B%97f%FD%1C%7Bvy WAYNE, N.J., June 17 /PRNewswire/ - Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer and agents targeting the Wnt pathway have the potential to be developed as pan-tumor drugs. The strategic alliance provides Bayer with the option to exclusively license antibody and protein therapeutic product candidates at any point up to the completion of Phase I testing. In addition, Bayer and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97f%FD%1Cxv%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/0acda5/bayer_schering_pha) has announced the addition of the "Bayer Schering Pharma AG - SWOT Analysis" company profile to their offering. Bayer Schering Pharma AG - SWOT Analysis The Bayer Schering Pharma AG - SWOT Analysis company profile is the essential source for top-level company data and information. Bayer Schering Pharma AG - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Bayer Schering, a business division of Bayer, is one of the largest pharmaceutical companies in the (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v6/%3B%97f%FE%12yx%7B 11.06.2010 - Protagen AG and Bayer Schering Pharma AG announced the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis. Endometriosis is a debilitating gynecological medical condition occuring in roughly 5% -10% of women worldwide. The golden standard of diagnosis is currently performed by laparoscopy, a visual inspection of the abdominal organs followed by surgical removal and examination of lesions. Aim of the current study is to evaluate the UNIarray technology for discovery of autoantibody patterns for the predictive diagnosis of Endometriosis and to improve patient s quality of life. Proteomic profiling of inflammation, angiogenesis and tissue (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v6/%3B%97f%FE%12%7Ev%7B Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors. MT110 is designed to direct a patient's T cells, the immune system's most potent killer cells, against cancer cells that express the epithelial cell adhesion molecule (EpCAM). Professor Walter Fiedler, University Hospital Hamburg-Eppendorf, Germany and the study's principal investigator, presented the data today at the American Society of Clinical Oncology Annual Meeting (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v6/%3B%97f%FE%12%7Exx CHICAGO - The investigational alpha-pharmaceutical radium-223 chloride (Alpharadin) appears to confer multiple benefits in men with metastatic castration-resistant prostate cancer (CRPC), researchers announced at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Results in two open-label phase 1 trials and three double-blind phase II trials showed that the agent improved survival, reduced pain, and had a tolerable safety profile when used to treat men with CRPC with bone metastases. Bone metastases are the main cause of disability and death in men with CRPC. Dr. Sten Nilsson, with Karolinska University Hospital in Stockholm, Sweden, was the lead investigator in (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97f%FE%12%7D%7E%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c90f85/bayer_schering_pha) has announced the addition of the "Bayer Schering Pharma AG - SWOT Framework Analysis" company profile to their offering. Bayer Schering Pharma AG - SWOT Framework Analysis SWOT Analysis, is a strategic planning tool used to evaluate the Strengths, Weaknesses, Opportunities, and Threats involved in a project or in a business venture. It involves specifying the objective of the business venture or project and identifying the internal and external factors that are favorable and unfavorable to achieving that objective. The aim of any SWOT analysis is to identify the key (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97f%FF%12%7Dwz CHICAGO-(BUSINESS WIRE)-A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary hepatocellular cancer (HCC) including those with disease that has spread outside the liver, according to the results of a prospective clinical study presented today at the 46th American Society of Clinical Oncology (ASCO) conference. The multi-center Phase II study was conducted by the Asia Pacific Hepatocellular Carcinoma Trials Group (AHCC) headed by Professor Pierce Chow, Senior Consultant, Singapore General Hospital and Visiting Senior Consultant, National (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97f%FF%12%7Dvx WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of the first clinical data for the Company s IMGN388 anticancer compound at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, IL. In this dose-escalation trial, IMGN388 has demonstrated favorable tolerability at the dose levels evaluated to date, and evidence of activity is being reported now that higher doses are starting to be evaluated. Dose escalation is continuing. We re encouraged by the clinical findings with IMGN388 œWe re encouraged by the clinical findings (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v6/%3B%97f%FF%12%7Cz%7B CAMBRIDGE, Mass.-(BUSINESS WIRE)-Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the appointment of Marc Rubin, M.D. to its Board of Directors. Dr. Rubin brings extensive clinical development, medical, commercial and scientific expertise to Curis, having held executive-level clinical development positions with Bayer Schering Pharma, Schering AG and GlaxoSmithKline. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97f%FF%13t%7B%7C WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of clinical data from a Phase Ib/II trial conducted by Roche and Genentech to investigate the safety and preliminary efficacy of trastuzumab-DM1 (T-DM1) used in combination with Roche s investigational antibody, pertuzumab. The findings were reported at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, IL (abstract #1012). The tolerability seen with TAP compounds when used as single agents supports assessing them as part of combination regimens The data reported provide (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97f%FF%11%7Exx CAMBRIDGE, Mass.-(BUSINESS WIRE)-Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the appointment of Marc Rubin, M.D. to its Board of Directors. Dr. Rubin brings extensive clinical development, medical, commercial and scientific expertise to Curis, having held executive-level clinical development positions with Bayer Schering Pharma, Schering AG and GlaxoSmithKline. We are very pleased to have Dr. Rubin join our board. We expect that his addition will enhance the expertise of the board as it guides Curis forward in its effort to become a leading small molecule cancer (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v6/%3B%97f%FF%14%7Exr CAMBRIDGE, Mass.-(BUSINESS WIRE)-Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the appointment of Marc Rubin, M.D. to its Board of Directors. Dr. Rubin brings extensive clinical development, medical, commercial and scientific expertise to Curis, having held executive-level clinical development positions with Bayer Schering Pharma, Schering AG and GlaxoSmithKline. text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v6/%3B%97f%FF%14%7D%7Dx Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced that it will report new data on its proprietary oncology diagnostic platform, a novel technology that forms the basis of the Company's recently announced collaboration with Bayer Schering Pharma AG. The new data will be highlighted in three separate presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago: - Analysis of truncated HER2 expression and activation in breast cancer, a poster presentation by Sharat Singh, Ph.D., Vice President of Diagnostic R&D for Prometheus, on Saturday, June 5 from 2:00 pm to 6:00 pm (CDT) - Use of SPARC, EGFR, and VEGFR (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97f%FF%15uzr NEW YORK-(BUSINESS WIRE)-WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced today that they have entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer s disease (AD) and related disorders are currently being diagnosed and treated. Through this collaboration, the two companies will develop specific markers that will aid in the diagnostics and management of Tau-protein related AD using brain-imaging technology. The diagnostics they are jointly aiming to develop will have application in disease treatment and potentially disease prevention. I am delighted with this agreement with Bayer Schering (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97f%FF%15uzx WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN) announced today that Daniel Junius, President and CEO, will present at two investor conferences next week. These presentations will be webcast live and can be accessed through the œInvestor Information  section of the Company s website, www.immunogen.com. An archive of these webcasts will be available at the same location until June 18, 2010. Morgan Joseph Best Ideas ConferenceWednesday, June 9, 2010 at 3:00 p.m. ETNew York, NY Jefferies 2010 Global Life Sciences ConferenceThursday, June 10, 2010 at 4:30 p.m. ETNew York, NY About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v6/%3B%97g%F6%12%7B%7C%7F NEW YORK-(BUSINESS WIRE)-WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced today that they have entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer s disease (AD) and related disorders are currently being diagnosed and treated. Through this collaboration, the two companies will develop specific markers that will aid in the diagnostics and management of Tau-protein related AD using brain-imaging technology. The diagnostics they are jointly aiming to develop will have application in disease treatment and potentially disease prevention. text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/goto/v6/%3B%97g%F6%10xxs ScienceDaily (June 1, 2010) Many tumor cells would not be viable due to aberrant chromosome distribution if they had not developed a special trick. Scientists from the German Cancer Research Center have investigated which genes are responsible for this survival strategy of cancer cells. The revealed that cancer cells rely on the tension of specific protein fibers to be able to multiply. Thus, proteins which maintain this tension are promising targets for new, target-specific anticancer drugs: If they are switched off, cancer cells die. See Also: Health & Medicine Brain Tumor Lung Cancer Cancer Prostate Cancer Ovarian Cancer Colon Cancer Reference Mitosis Somatic cell Embryonic stem cell (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v6/%3B%97g%F6%10x%7F%7F Who said that learning about bugs was boring? An amazing new journey through the wonderful world of parasites launches on YouTube today. Four exciting videos, inspired by the 'Parasites Life Undercover' exhibition at the Berlin Natural History Museum and developed by Bayer Animal Health, showcase some fascinating highlights from the exhibition and provide useful information about protecting your pets. Join celebrity vet, Scott Miller, as he discusses all kinds of parasites including fleas, mosquitoes and even vampire bats, and watch as he shows us how they can harm our pets and what we should do to protect against them. Scott says, 'As a vet I would strongly recommend that owners (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%F8%17%7Ez%7D WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company s Targeted Antibody Payload (TAP) technology at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on June 4-8, 2010. These presentations at ASCO will include the first clinical data for our IMGN388 compound for solid tumors, and also the first data for a TAP compound used in a combination regimen œThese presentations at ASCO will include the first clinical data for our IMGN388 compound for solid (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%F9%17zv%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/38408a/multiple_sclerosis) has announced the addition of the "Multiple Sclerosis Therapeutics - Global Strategic Business Report" report to their offering. Multiple Sclerosis Therapeutics - Global Strategic Business Report This report analyzes the worldwide markets for Multiple Sclerosis Therapeutics in US$ Billion. The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 45 companies including Bayer Schering Pharma AG, Biogen Idec Inc., Elan (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%F9%14u%7C%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/a65c90/liver_cancer_drugs) has announced the addition of the "Liver Cancer Drugs - Global Strategic Business Report" report to their offering. Liver Cancer Drugs - Global Strategic Business Report This report analyzes the Global market for Liver Cancer Drugs in US$ Million. Annual estimates and forecasts are provided for the period 2007 through 2015. The report profiles 40 companies including 4SC AG, Actavis Group, Inc., Alnylam Pharmaceuticals, Inc., ArQule, Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Celsion Corp, Eli Lilly & Company, ImClone Systems Inc., F. HoffmannLa Roche Ltd., (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%F9%14t%7C%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d5a60b/neurodegenerative) has announced the addition of the "Neurodegenerative Drugs - Global Strategic Business Report" report to their offering. Neurodegenerative Drugs - Global Strategic Business Report This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million by the following disease types: Alzheimers Disease, Parkinsons Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Neurodegenerative Diseases. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%F9%14%7Bw%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/a64b93/competitor_analysi) has announced the addition of the "Competitor Analysis: Tuberculosis Vaccines and Therapeutics" report to their offering. The present Competitive Intelligence Report about Tuberculosis Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic small molecules against infection with Mycobacterium tuberculosis as of May 2010. Purchase of the PDF report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97g%F9%15uz%7F The aim of this study was to investigate the dose response relationship of dicentrics in human lymphocytes after CT scans at tube voltages of 80 and 140 kV. Blood samples from a healthy donor placed in tissue equivalent abdomen phantoms of standard, pediatric and adipose sizes were exposed at dose levels up to 0.1 Gy using a 64-slice CT scanner. It was found that both the tube voltage and the phantom size significantly influenced the CT scan-induced linear dose-response relationship of dicentrics in human lymphocytes. Using the same phantom (standard abdomen), 80 kV CT x-rays were biologically more effective than 140 kV CT x-rays. However, it could also be determined that the applied (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v6/%3B%97g%FA%12yxr In the most comprehensive study to date, neurologists have clearly identified significant differences in the ways that Alzheimer's disease (AD) affects patients with and without the apolipoprotein E µ4 gene (APOE µ4), a known genetic risk factor for the neurodegenerative disease, using a combination of cognitive and neuroanatomic measures. The study found that this gene influences the way the disease manifests, even at its mildest clinical stages. Study highlights include: - Patients with mild AD who carry the µ4 form of the APOE gene perform more poorly on memory tests and have more prominent abnormalities in brain regions critical for memory, compared with patients without this gene (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v6/%3B%97g%FA%17u%7Dy San Francisco Business Times - by Ron Leuty - Bayer HealthCare will establish a U.S. Innovation Center in Mission Bay, rotating researchers through the facility and working with UCSF in an attempt to build the German drug maker s product pipeline. The center at 455 Mission Bay South across Third Street from the University of California, San Francisco will house Bayer s hematology research program. But scientists focused on cardiology, oncology, women s health care and diagnostic imaging also will rotate through the center. The San Francisco Business Times reported last month that Bayer inked a lease for about 50,000 square feet at the structure, which was developed by Alexandria Real (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97g%FC%1D%7F%7D%7C The design, synthesis and pharmacological properties of a novel class of PPARalpha agonists is described. Compound 2 is a novel, potent and specific glycine amide with oral bioavailability in rodents. The compound is active in vivo and alters plasma lipids in hAPO-A1 transgenic mice after oral administration. |-| Bioorg Med Chem Lett. |-| Urbahns K, Woltering M, Nikolic S, Pernerstorfer J, Bischoff H, Dittrich-Wengenroth E, Lustig K. |-| Department of Medicinal Chemistry, Bayer Healthcare, Bayer-Schering Pharma, D-42096 Wuppertal, Germany. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%FC%16y%7D%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/0d03c8/china_the_key_pha) has announced the addition of the "China: The Key Pharmemerging Market - Deciphering Major Pharma Companies China Strategy" report to their offering. China: The Key Pharmemerging Market - Deciphering Major Pharma Companies China Strategy It has been widely recognized that a series of changes is currently underway in the global pharmaceutical industry. All world major pharma companies are currently experiencing a number of common challenges, both internally and externally. These challenges have forced them to take all necessary actions including reducing the size of their (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%FD%1Ctwy DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/7d6e84/dysmenorrhea_dru) has announced the addition of GlobalData's new report "Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering. Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts to 2016 Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts to 2016 which provides key data, information and analysis on the dysmenorrhea market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts for seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%FD%13yz%7E DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/765a1a/targeted_cancer_th) has announced the addition of Decision Resources, Inc.'s new report "Targeted Cancer Therapies: Novel Targets, Technologies, and Dealmaking" to their offering. Targeted Cancer Therapies: Novel Targets, Technologies, and Dealmaking The current flurry of research into the development of new drugs against novel cancer targets is unprecedented. Many pharmaceutical and biotech companies, drawn by the sustained success of approved targeted cancer therapies such as Avastin, Herceptin, Gleevec, and Rituxan, are conducting exploratory and clinical research on new targets. The fruit (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97g%FD%10%7Bvr Radiolabeled benzamides are attractive candidates for targeted radiotherapy of metastatic melanoma as they bind melanin and exhibit high tumor uptake and retention. One such benzamide, N-(2-diethylamino-ethyl)-4-(4-fluoro-benzamido)-5-iodo-2-methoxy-benzamide (MIP-1145), was evaluated for its ability to distinguish melanin-expressing from amelanotic human melanoma cells, and to specifically localize to melanin-containing tumor xenografts. The binding of [(131)I]MIP-1145 to melanoma cells in vitro was melanin dependent, increased over time, and insensitive to mild acid treatment, indicating that it was retained within cells. Cold carrier MIP-1145 did not reduce the binding, consistent with (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97g%FD%11z%7Er Metastatic bone disease caused by renal cell carcinoma (RCC) occurs frequently and becomes more and more prevalent presumably because survival times among patients with disseminated cancers are increasing. Patients with bone metastases from renal cell carcinoma suffer from severe pain, nerve compression syndromes and pathologic fractures. Very little is known about the mechanisms of skeletal metastases of RCC. Thus, to better understand the molecular mechanism of renal cell cancer (RCC) bone metastasis, it is crucial to develop new animal models. We have established a new animal model of RCC metastasis to bone by inoculation of human 786-O/luciferase cells into the left cardiac ventricle (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%FD%15%7C%7D%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/96d0ec/german_pharma_sect) has announced the addition of the "German Pharma Sector Analysis" report to their offering. Germany is one of the largest pharmaceutical markets in the world. Most of the pharma companies in Germany are focused on research, which has led the country to become one of the most advanced pharma markets in the world. The country's pharmaceutical market is estimated to have generated revenues of more than Euro 23 Billion (US$ 32.2 Billion) in 2009, and a consistent and strong growth is anticipated in the market for the next few years. Our latest research report German Pharma (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v6/%3B%97g%FE%11uwr 04.05.2010 - Algeta ASA announced that the sample size re-estimation of its pivotal ALSYMPCA clinical trial, which was pre-planned for the first half of 2010, was completed on schedule. The sample size re-estimation confirmed that the current plan to recruit 750 patients into the ALSYMPCA study will meet the goals originally set for the study. Algeta and its partner Bayer Schering Pharma AG have in parallel decided to increase recruitment for ALSYMPCA to 900 patients. This will increase the statistical power of the trial to 90% thereby further increasing the likelihood of proving the efficacy of Alpharadin. It will also allow the study to recruit US patients, and allow US clinical (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v6/%3B%97g%FE%11uy%7F NEW YORK, NY-(Marketwire - May 3, 2010) - U.S. primary care physicians (PCPs) have returned to expressing positive word of mouth about the pharmaceuticals industry, while in the main EU markets PCPs' attitudes to the industry are still fairly negative. Among oncologists, only those in the UK express a strongly favorable attitude toward the industry, according to new research from Kantar Health, a leading healthcare-focused global consultancy and marketing insights company. "The particular customer sentiment that a company faces - interpreted as either positive or negative word of mouth - has a major impact on a company's performance," says Mark Sales, Kantar Health's Head of Global (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97g%FE%11t%7E%7E NORWALK, Conn.-(BUSINESS WIRE)-Gerard WM van Odijk , President & CEO of Teva Pharmaceuticals Europe B.V., will get face-to-face with an audience of senior biopharma executives at Windhover Conferences 17th annual Euro-Biotech Forum, to be held June 28-30 in Paris. Also on tap is a three-way panel to discuss three of the most strategically interesting deals of the year with the dealmakers who created them: Iain Buchanan, CEO, Novexel SA on the AstraZeneca/Novexel deal; Jean-Luc Belingard, Chairman and CEO, Ipsen, on the Ipsen/Inspiration deal; and Beth Fordham-Meier, Senior Director of Business Development, Targacept, on the AstraZeneca/Targacept deal. Euro-Biotech Forum, this year (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v6/%3B%97g%FE%11y%7B%7F CHICAGO, May 3 /PRNewswire/ - Global biotechnology and pharmaceutical companies that seek to capitalize on Asia's growth story are locating first-in-Asia manufacturing facilities and headquarters offices in Singapore. Fixed asset investments from biomedical companies exceeded US$800 million in 2009. "Asia's growth presents tremendous opportunities but its diversity also poses challenges. In global companies' foray into Asia, Singapore can help to enhance manufacturing and business excellence to strengthen their foothold in Asia," said Mr. Beh Kian Teik, Director, Biomedical Sciences, Singapore Economic Development Board (EDB). Core Site of Manufacturing Excellence in Asia In 2009, Baxter, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v6/%3B%97g%FF%12%7Bz%7B Zurich-Schlieren, Switzerland, April 30, 2010. Molecular Partners AG, the global leader in the development of DARPins as unique next generation protein therapeutics, announced today that it has enrolled the first cohorts of patients in two separate Phase I trials in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The trials are investigating the safety and tolerability of a single intravitreal injection of MP0112, a DARPin which inhibits all relevant forms of vascular endothelial growth factor A (VEGF-A) with high potency. The studies will also allow a preliminary assessment of efficacy and the duration of action of MP0112. MP0112 was engineered to have a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97g%FF%11xvz BACKGROUND AND PURPOSE: Cysteinyl leukotrienes (CysLTs) have been implicated in the pathophysiology of inflammatory and cardiovascular disorders. Their actions are mediated by CysLT(1) and CysLT(2) receptors. Here we report the discovery of 3-({[(1S,3S)-3-carboxycyclohexyl]amino}carbonyl)-4-(3-{4-[4-(cyclo-hexyloxy)butoxy]phenyl}propoxy) benzoic acid (HAMI3379), the first potent and selective CysLT(2) receptor antagonist. EXPERIMENTAL APPROACH: Pharmacological characterization of HAMI3379 was performed using stably transfected CysLT(1) and CysLT(2) receptor cell lines, and isolated, Langendorff-perfused, guinea pig hearts. KEY RESULTS: In a CysLT(2) receptor reporter cell line, HAMI3379 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97g%FF%16%7Cxy PURPOSE: To quantify differences in regional myocardial perfusion in coronary artery stenosis by the use of dual source computed tomography (DSCT) in an animal model. MATERIAL AND METHODS: In 5 pigs, an 80% stenosis of the left anterior descending artery was successfully induced by partial balloon occlusion (ischemia group). Five animals served as control group. All animals underwent contrast enhanced whole heart DSCT (Definition Flash, Siemens, Germany) perfusion imaging using a prototype electrocardiogram -triggered dynamic scan mode. Imaging was performed at rest as well as under stress conditions during continuous infusion of adenosine (240 mg/kg/min). For contrast enhancement 60 mL (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97%60%F6%1Dywr Sorafenib (Nexavar) is a novel oral Raf kinase and vascular endothelial growth factor receptor inhibitor. Most anti-cancer drugs are substrates for ABC efflux pumps especially for P-glycoprotein (P-gp). To evaluate the influence of P-gp on the pharmacokinetics of sorafenib substrate properties for this transporter were investigated. Therefore, permeability of sorafenib across Caco-2 and P-gp overexpressing cells was determined. To determine the in vivo relevance of these in vitro findings, pharmacokinetics of sorafenib in mdr1a/1b(-/-) and wild-type (WT) mice was studied. Sorafenib is highly permeable and exhibits a slight efflux across Caco-2 cells. In P-gp overexpressing cells a small (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97%60%F7%12%7Bys DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/33724f/china_pharmaceutic) has announced the addition of the "China Pharmaceuticals and Healthcare Report Q2 2010" report to their offering. China Pharmaceuticals and Healthcare Report Q2 2010 China Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on China's pharmaceuticals and healthcare industry. In February 2010, the authors upgraded Chinas patented drug market forecast following clarification of the country's (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v6/%3B%97%60%F8%16%7Bz%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/7ef2c6/picture_this_reve) has announced the addition of Decision Resources, Inc.'s new report "Picture This: Revealing Trends for a More Robust Diagnostic Imaging Industry" to their offering. Picture This: Revealing Trends for a More Robust Diagnostic Imaging Industry What will it take to make diagnostic imaging a more robust industry sector? On the one hand, imaging technology - a standard technique in diagnosing and managing cancers and neurological and cardiovascular diseases - faces resistance, deriving mainly from concerns over cost and safety, that prevents it from reaching its full potential. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97%60%F8%14%7Bxx Purpose: To investigate the potential of multi-slice computed tomography (MSCT) as a tool for non-invasive temperature measurement. Materials and methods: Samples of water, 0.9% saline, sunflower oil and dilutions of (1:32, 1:64, 1:128) contrast agent (Iopromid 370, BayerSchering Pharma, Berlin) were heated in a plexiglass phantom. In a first set-up, samples of 0.9% saline solution were scanned at defined temperatures (25 degrees -75 degrees C; 5 degrees C intervals) using a clinical CT scanner. Scan parameters (tube current-time product, tube voltage, collimation, slice thickness) were systematically varied. In a second set-up samples of the different fluids (water, sunflower oil, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97%60%FA%15z%7Ez OBJECTIVE: The iodinated contrast agents (CAs) that are currently used in radiographic procedures possess special physicochemical properties and a high safety profile; however, according to a large retrospective study (Swedish registry), the viscosity of CAs may have an underestimated impact on renal failure. The aim of our study was to investigate the possible consequences of CA viscosity differences, such as CA retention in the kidney. MATERIAL AND METHODS: Five Göttingen minipigs were each intravenously injected in a crossover setting at intervals of at least 7 days with monomeric (Iopromide) and dimeric (Iodixanol) CAs at 2 doses (1 and 2 g iodine/kg bodyweight), and the retention of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v6/%3B%97%60%FB%12t%7Cr The need for development and validation of in vitro hormone receptor transactivation assays as important alternative tools to study interactions with sex hormone receptors is outlined by international organisations, as such assays should be included in the OECD conceptual framework for the testing and assessment of endocrine active chemicals. Therefore as part of the European Union (EU)-sponsored 6th framework project ReProTect, the validation study with MELN cells, MCF-7 cells (ER+, estrogen receptor positive) which were stably transfected with the estrogen responsive gene ERE-betaGlob-Luc-SVNeo was set up. Standard operating procedures including a prescreen assay for unknown chemicals, (…)